» Articles » PMID: 29904242

Noninvasive Imaging of Hepatocellular Carcinoma: From Diagnosis to Prognosis

Overview
Specialty Gastroenterology
Date 2018 Jun 16
PMID 29904242
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a major public health problem worldwide. Hepatocarcinogenesis is a complex multistep process at molecular, cellular, and histologic levels with key alterations that can be revealed by noninvasive imaging modalities. Therefore, imaging techniques play pivotal roles in the detection, characterization, staging, surveillance, and prognosis evaluation of HCC. Currently, ultrasound is the first-line imaging modality for screening and surveillance purposes. While based on conclusive enhancement patterns comprising arterial phase hyperenhancement and portal venous and/or delayed phase wash-out, contrast enhanced dynamic computed tomography and magnetic resonance imaging (MRI) are the diagnostic tools for HCC without requirements for histopathologic confirmation. Functional MRI techniques, including diffusion-weighted imaging, MRI with hepatobiliary contrast agents, perfusion imaging, and magnetic resonance elastography, show promise in providing further important information regarding tumor biological behaviors. In addition, evaluation of tumor imaging characteristics, including nodule size, margin, number, vascular invasion, and growth patterns, allows preoperative prediction of tumor microvascular invasion and patient prognosis. Therefore, the aim of this article is to review the current state-of-the-art and recent advances in the comprehensive noninvasive imaging evaluation of HCC. We also provide the basic key concepts of HCC development and an overview of the current practice guidelines.

Citing Articles

The value of contrast-enhanced ultrasound fusion imaging in percutaneous liver biopsy for liver lesions invisible on conventional B-mode ultrasound.

He Y, Gong L, Wu J, Wen B, Kong W Quant Imaging Med Surg. 2025; 15(2):1528-1542.

PMID: 39995703 PMC: 11847198. DOI: 10.21037/qims-24-1104.


Risk-stratified hepatocellular carcinoma screening according to the degree of obesity and progression to cirrhosis for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan: a cost-effectiveness study.

Kowada A BMJ Open. 2024; 14(11):e080549.

PMID: 39500609 PMC: 11552604. DOI: 10.1136/bmjopen-2023-080549.


Multisequence MRI-Based Radiomic Features Combined with Inflammatory Indices for Predicting the Overall Survival of HCC Patients After TACE.

Zhou M, Zhang P, Mao Q, Shi Y, Yang L, Zhang X J Hepatocell Carcinoma. 2024; 11:2049-2061.

PMID: 39469284 PMC: 11514804. DOI: 10.2147/JHC.S481301.


Prognostic value of AFP-L3 and Des-γ-carboxy prothrombin in advanced primary liver cancer treated with Sorafenib and transarterial chemoembolization.

Tang S, Liu H, Chen P, He J, Chen H, Chen J Am J Transl Res. 2024; 16(9):5004-5010.

PMID: 39398579 PMC: 11470304. DOI: 10.62347/PMYP4404.


Liquid Chromatography/Tandem Mass Spectrometry-Based Simultaneous Analysis of 32 Bile Acids in Plasma and Conventional Biomarker-Integrated Diagnostic Screening Model Development for Hepatocellular Carcinoma.

Yamauchi M, Maekawa M, Sato T, Sato Y, Kumondai M, Tsuruoka M Metabolites. 2024; 14(9).

PMID: 39330520 PMC: 11433973. DOI: 10.3390/metabo14090513.


References
1.
Sia D, Villanueva A, Friedman S, Llovet J . Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology. 2017; 152(4):745-761. DOI: 10.1053/j.gastro.2016.11.048. View

2.
Nishie A, Yoshimitsu K, Asayama Y, Irie H, Tajima T, Hirakawa M . Radiologic detectability of minute portal venous invasion in hepatocellular carcinoma. AJR Am J Roentgenol. 2007; 190(1):81-7. DOI: 10.2214/AJR.07.2810. View

3.
Venkatesh S, Yin M, Glockner J, Takahashi N, Araoz P, Talwalkar J . MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol. 2008; 190(6):1534-40. PMC: 2894569. DOI: 10.2214/AJR.07.3123. View

4.
Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

5.
Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y . JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2015; 3(3-4):458-68. PMC: 4531423. DOI: 10.1159/000343875. View